A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
A phase 3 trial testing Vepugratinib in bladder & urothelial cancer, now recruiting.
Overview
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract is a phase 3 interventional study registered as NCT07218380, led by Eli Lilly and, and recruiting when checked on 2026-09-11. Official title: FORAGER-2: A Phase 3, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration. Planned enrolment is 450 participants (estimated). The study started in 2025-12-12 and primary completion is expected in 2029-10. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Shares Eli Lilly (incl. Loxo) and the tag ctgov-ingest.
- TrialA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Shares Eli Lilly (incl. Loxo) and the tag ctgov-ingest.
- TrialA Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Shares Bladder & urothelial cancer and the tag ctgov-ingest.